GNOM Fact Sheet: Global X Genomics & Biotechnology ETF
Share
$57.08
close, Nov 20, 2026
Over the year to Nov 19, 2026, GNOM returned +39.6% in total and charged 0.50% a year.
- 1-year total return
- +37.2%
- to Nov 20, 2026
- Expense ratio
- 0.50%
- a year
- Net assets
- $108m
- on Nov 11, 2026
- Net flow, 12 months to Aug 31, 2026
- +$2.5m
- daily basis to Nov 11, 2026
Growth of $10,000, 1 year
GNOM $13,965 +39.6% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−16.9%
3 months−14.5%
Year to date+25.7%
1 year+37.2%
3 years+40.6%
5 years−32.5%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
MODERNA, INC.7.50%
Twist Bioscience Corporation6.34%
10x Genomics, Inc.5.48%
GUARDANT HEALTH, INC.5.28%
ILLUMINA, INC.4.87%
NATERA, INC.4.61%
Genscript Biotech Corp3.81%
VERTEX PHARMACEUTICALS INCORPORATED3.70%
BIO-TECHNE CORPORATION3.67%
BIOMARIN PHARMACEUTICAL INC.3.58%
GNOM top ten by weight, 48.8% of the fund, of its 50 equity positions, from the holdings filed for Aug 31, 2026.
Facts
Holds 50 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies · First traded Apr 10, 2019 · Benchmark Its own holdings, as of Nov 11, 2026